Fondaparinux in Acute Coronary Syndrome
Fondaparinux is an effective anticoagulant for ACS patients managed conservatively or with fibrinolytic therapy, but it must NOT be used to support PCI due to increased catheter thrombosis risk. 1
Dosing Recommendations
Initial Therapy (NSTE-ACS or STEMI without immediate PCI)
- 2.5 mg subcutaneous once daily 1
With Fibrinolytic Therapy (STEMI)
- 2.5 mg IV bolus initially
- Then 2.5 mg subcutaneous once daily starting the following day 1
- This regimen is a Class 1, Level B-R recommendation for STEMI patients not undergoing an invasive approach 1
The 2025 ACC/AHA/SCAI guidelines specifically endorse fondaparinux as a recommended alternative to enoxaparin for reducing ischemic events in STEMI patients treated with fibrinolytics who are managed conservatively 1. This recommendation is based on the OASIS-6 trial, which demonstrated reduced death and reinfarction rates compared to usual care.
Key Indications
Fondaparinux is appropriate for:
- NSTE-ACS patients managed medically (without planned PCI)
- STEMI patients receiving fibrinolytic therapy
- STEMI patients not undergoing early reperfusion therapy
The OASIS-5 trial demonstrated that fondaparinux was similar to enoxaparin for ischemic events at 9 days in NSTE-ACS patients but significantly reduced major bleeding 1.
Critical Contraindications
Absolute Contraindications 2
- Severe renal impairment (CrCl <30 mL/min) - this is explicitly stated in both guidelines and FDA labeling 1, 2
- Active major bleeding
- Bacterial endocarditis
- Thrombocytopenia with positive anti-platelet antibody in presence of fondaparinux
- Body weight <50 kg (for VTE prophylaxis only; not an absolute contraindication for ACS)
- History of serious hypersensitivity reaction to fondaparinux
Procedural Contraindication
Fondaparinux should NOT be used to support PCI (Class 3: Harm, Level B-R) 1
This is a critical clinical pitfall. The OASIS-5 trial showed an increased rate of guiding-catheter thrombus formation with fondaparinux (0.9% vs 0.3% with enoxaparin) 1. If a patient on fondaparinux requires urgent PCI, add unfractionated heparin to prevent catheter thrombosis.
Clinical Algorithm for Use
Step 1: Assess renal function
- If CrCl <30 mL/min → Do NOT use fondaparinux 1, 2
- Choose alternative anticoagulant (UFH or bivalirudin)
Step 2: Determine management strategy
- If PCI planned → Do NOT use fondaparinux; use UFH, enoxaparin, or bivalirudin 1
- If fibrinolytic therapy planned → Fondaparinux is recommended (2.5 mg IV, then 2.5 mg SC daily) 1
- If conservative/medical management → Fondaparinux is appropriate (2.5 mg SC daily) 1
Step 3: If patient on fondaparinux requires emergent PCI
- Add UFH bolus during procedure to prevent catheter thrombosis 1
Advantages Over Other Anticoagulants
Fondaparinux offers several benefits:
- Once-daily dosing without need for monitoring 1
- Reduced major bleeding compared to enoxaparin in OASIS-5 trial 1
- No heparin-induced thrombocytopenia risk 3
- Predictable pharmacokinetics with 100% bioavailability 4
- Mortality benefit in STEMI patients (OASIS-6 trial) 4, 5
Special Populations
Low Body Weight Patients
While the FDA label lists body weight <50 kg as a contraindication for VTE prophylaxis 2, the ACS dosing remains 2.5 mg daily regardless of weight 1. However, one study showed higher anti-Xa activity after the second dose in patients <50 kg, though still within expected therapeutic range 6. Monitor closely for bleeding in low-body-weight patients.
Obesity
The 2024 ESC consensus suggests no dose adjustment is needed for fondaparinux in obese patients for ACS, though data are limited 7. The fixed 2.5 mg daily dose is used regardless of body weight for ACS 1.
Hepatic Impairment
No dose adjustment needed for mild-to-moderate hepatic impairment, but observe closely for bleeding 2. Data unavailable for severe hepatic impairment.